> Details

Ferrari Aggradi, Carola Rita; Rimoldi, Martina; Romagnoli, Gloria; Velardo, Daniele; Meneri, Megi; Iacobucci, Davide; Ripolone, Michela; Napoli, Laura; Ciscato, Patrizia; Moggio, Maurizio; Comi, Giacomo Pietro; Ronchi, Dario; Corti, Stefania; Abati, Elena

Lafora Disease: A Case Report and Evolving Treatment Advancements

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Lafora Disease: A Case Report and Evolving Treatment Advancements
  • Contributor: Ferrari Aggradi, Carola Rita; Rimoldi, Martina; Romagnoli, Gloria; Velardo, Daniele; Meneri, Megi; Iacobucci, Davide; Ripolone, Michela; Napoli, Laura; Ciscato, Patrizia; Moggio, Maurizio; Comi, Giacomo Pietro; Ronchi, Dario; Corti, Stefania; Abati, Elena
  • Published: MDPI AG, 2023
  • Published in: Brain Sciences, 13 (2023) 12, Seite 1679
  • Language: English
  • DOI: 10.3390/brainsci13121679
  • ISSN: 2076-3425
  • Keywords: General Neuroscience
  • Origination:
  • Footnote:
  • Description: Lafora disease is a rare genetic disorder characterized by a disruption in glycogen metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during adolescence. Pathognomonic is the presence of abnormal glycogen aggregates that, over time, produce large inclusions (Lafora bodies) in various tissues. This study aims to describe the clinical and histopathological aspects of a novel Lafora disease patient, and to provide an update on the therapeutical advancements for this disorder. A 20-year-old Libyan boy presented with generalized tonic–clonic seizures, sporadic muscular jerks, eyelid spasms, and mental impairment. Electroencephalography showed multiple discharges across both brain hemispheres. Brain magnetic resonance imaging was unremarkable. Muscle biopsy showed increased lipid content and a very mild increase of intermyofibrillar glycogen, without the polyglucosan accumulation typically observed in Lafora bodies. Despite undergoing three lines of antiepileptic treatment, the patient’s condition showed minimal to no improvement. We identified the homozygous variant c.137G>A, p.(Cys46Tyr), in the EPM2B/NHLRC1 gene, confirming the diagnosis of Lafora disease. To our knowledge, the presence of lipid aggregates without Lafora bodies is atypical. Lafora disease should be considered during the differential diagnosis of progressive, myoclonic, and refractory epilepsies in both children and young adults, especially when accompanied by cognitive decline. Although there are no effective therapies yet, the development of promising new strategies prompts the need for an early and accurate diagnosis.
  • Access State: Open Access